Shows over 3 mil on a three month average. over the last 30 days it doesn't appear to have broken two million. Buy and hold here. Interest is low but this isn't going much lower.
Indeed, brachytherapy offers numerous advantages over other treatment options. It is as efficient as other treatment options, has fewer side effects and is cost effective. Given these factors, sooner rather than later, brachytherapy will become the treatment of choice for early stage prostate cancer.
One of the most promising companies in the brachytherapy space is IsoRay Inc. (NYSEMKT: ISR), a Richland, Washington-based company engaged in the development, manufacture and sale of Cesium-131, a radioisotope used in brachytherapy.
ISR’s Cesium-131 has numerous advantages over other radioisotopes. It has superior energy and the shortest half-life, which makes it an effective treatment option not just for prostate cancer but also for other forms of aggressive cancer.
IsoRay’s sole focus over the past decade has been to increase awareness of Cesium-131 among the patient and the medical community. And it has been successful in this regard as evidenced by the company’s shares performance in 2014. Last year, ISR shares were among the top performers on the NYSEMKT, gaining more than 190%.
The gains came on the back of some successful peer-reviewed studies that highlighted the effectiveness of Cesium-131.
On Wednesday, ISR announced its financial results for the quarter ended December 31, 2014. At the end of the quarter, the company had $20 million in cash on its balance sheet and no debt. This is very unusual for an early-stage company like IsoRay. However, the financial situation highlights the astuteness of the management, which took advantage of the surge in stock price last year and completed a secondary offering.
Given ISR’s robust cash position and current burn rate, the company will not need any additional cash for at least the next five years. This completely takes out the dilution risk, which is usually associated with early stage companies like IsoRay.
On the operating front, the company has not been doing too badly either. It remains committed to diversifyi
Sentiment: Strong Buy
So two more days and we are half way through February. Volume is dead. Am I the only one that is starting to doubt this big run this month? Would love to see the "explosion to 0.50-1.00." any day now. Just sayin. Thoughts on the dead silence, volume, lame news as of late? TIA
I am long but feel like the good uplisting news will have a reverse split included. I mean this stock has traded sideways for a while now. Then a sudden drop. I was beginning to believe the sideways action was a way to obtain an average price for an uplisting. Just sayin I want it to run to a buck as well don't get me wrong but uplisting looks to be happening quite rapidly. I mean what is the minimum price for the Nasdaq? Serious discussion here. Short or long whatever. Thanks
This was written Sept 2013...
M&A activities in the cancer therapy market often take place. Big players like Amgen, Pfizer and Merck have billions in cash and boast a long list of take-overs. A recent example is Amgen's take-over of Onyx Pharmaceuticals. Other examples can be found on the internet. Given the unique FDA approved product line of Isoray and the tiny market capitalization below $20 million, there is a reasonable chance one of the bigger companies gobbling up Isoray in the near future.
We view Isoray therefore as an interesting take-over target.
Been some time this has been written. With all the silence it might be time for this to finally occur.
Sentiment: Strong Buy
So clearly my trading app was screwing up today. Just logged in to check it and it said NVIV was 127 dollars a share. Lol. I almost sent a mass email at my job like "I quit!" Unfortunately it's not true.
But seriously does a 500% long term win exist here? Possibly. A slow climb will continue to 1.75 range over the next week or two. Maybe settle in the 1.90s. But if any news hits in the next 60 days that states "feeling in _____ was restored." Watch out. Been following this company for over four years now. If "it" is gonna happen it's the next two months. January Effect Material right here. Good luck
This should be a long term sentiment disclosure. 75% of people on this board are up over 50%. So why even listen to any bear on here? Be nice if bears gave alternatives to my bad investment.
That's the catylst of all catylsts here. That's coming I think first of the year.